Q BioMed Inc. (QBIO)
| Market Cap | 14.51K |
| Revenue (ttm) | 209.29K |
| Net Income (ttm) | -1.91M |
| Shares Out | 145.09M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,200 |
| Average Volume | 7,668 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 157.12 |
| RSI | 53.07 |
| Earnings Date | Apr 11, 2025 |
About Q BioMed
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a part... [Read more]
Financial Performance
In 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$3.49 million, -60.03% less than in 2021.
Financial StatementsNews
Q BioMed Inc. Provides Update to Shareholders
NEW YORK , June 23, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health...
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthc...
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
Uttroside B Has Shown Promising Results in Initial Pre-Clinical Testing NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused...
Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.
Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commerc...
Q BIOMED PROVIDES SHAREHOLDER UPDATE
Focus on Portfolio Monetization and Roll-up Strategy NEW YORK , Oct. 11, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased...
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
Groundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression in Glaucoma The Certificate of Grant and European Patent No. 3408287 for GDF15 IN GLAUCOMA...
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issue...
Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets
Management's assessment and value of Q BioMed outlined NEW YORK , May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy an...
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer
NEW YORK , March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development ...
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market
NEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Inje...
Q BioMed Outlines Strategic Direction for 2022
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines s...
Q BioMed Shows Significant Uptrend in Revenues in Year-End Update
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline...
Q BioMed Inc. Provides Shareholder Update
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health...
Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthc...
Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatmen...
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthca...
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoS...
Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East
NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, ...
Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company...
Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience
NEW YORK, May 20, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in cre...
Q BioMed Insider to Invest up to $30M in the Company
NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a pri...
Q BioMed Updates Shareholders
NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Resea...
Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs
NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injec...
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Or...
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designat...